This webinar session, Tuberculosis: A Disease Neglected, Misunderstood, but Deadly, provides a comprehensive overview of TB’s microbiology, pathophysiology, and current epidemiology, along with effective strategies for public health prevention and clinical management. Facilitated by Gavin Harris, MD (Emory University), the program features didactic instruction from Marcos C.

his webinar session features a case-based discussion on the management of tuberculosis in alignment with the 2025 ATS/CDC/ERS/IDSA Clinical Practice Guidelines. Lahari Tumuluri, MD (Tulane University), will present two TB cases illustrating the application of these guidelines. Jussi Saukkonen, MD (Boston University), and Charles Daley, MD (National Jewish), will review the guideline development process, supporting evidence, and practical implications for treating drug-sensitive and drug-resistant TB, drawing on real-world clinical experience.

The webinar is to enhance community medical providers’ awareness of latent tuberculosis infection (LTBI). A brief overview of latent tuberculosis vs. active tuberculosis is given along with the most recent numbers of TB cases in NYS and CDC estimates of those with LTBI. It encourages community providers to assess their patients for TB risk factors, then test and treat them for LTBI as indicated.

This fact sheet discusses how research from the University of California San Diego and published in Clinical Infectious Diseases, estimates the hepatitis A vaccination coverage needed to prevent outbreaks among people who inject drugs (PWID). Analyzing surveillance data from 16 states with recent hepatitis A outbreaks linked to PWID, the study found that vaccination coverage of at least 80% may be necessary to reliably achieve herd immunity—though some states, such as West Virginia, may require higher levels.

This webinar features a presentation from the March 2024 Conference on Retroviruses and Opportunistic Infections (CROI), where Dr. Patrick Sullivan—AIDSVu Principal Scientist and Professor at Emory University—presented the oral abstract, “Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012–2021.” Using real-world data on PrEP coverage, Dr. Sullivan’s study found that states with a higher proportion of people with PrEP indications who were using PrEP experienced steeper declines in new HIV diagnoses over the past decade.

This video educates viewers on what the PrEP-to-Need Ratio is and how to properly use it to evaluate health equity.

This video walks through AIDSVu Location Profiles -- interactive, user-friendly summaries of HIV data for various locations across the U.S., including cities, counties, states, and regions. These profiles provide insights into HIV prevalence, new diagnoses, mortality, and more, helping users understand the impact of HIV in their communities.

This webinar recording discusses how the hepatitis A landscape is changing globally. Between 2010 and 2019, the number of deaths from hepatitis A decreased globally by 10%, despite the number of cases increasing by 4%. A number of factors have helped drive these changes, including globalization and increased hepatitis A vaccination rates.